Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 44

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 44
---
 the later of August 26, 2025, (the six month anniversary of the date of
issuance) and the Stockholder Approval Date there is no effective registration statement under the Securities Act for the resale of the
New Warrant Shares, any holder may, in its sole discretion, elect to exercise New Warrants through a cashless exercise, in which case
such holder would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in
the New Warrant.

The exercise
price of the New Warrants, and the number of New Warrant Shares, are subject to adjustment in the event of any stock dividend or split,
reverse stock split, recapitalization, reorganization, or similar transaction, as described in the New Warrants. In addition, the New Warrants provide that we may also, at any time during the term of the New Warrants, subject to the prior written consent of the applicable holder, voluntarily reduce the then-current exercise price to any amount and for any period of time, subject to the rules and regulations of Nasdaq.

A holder will not have the
right to exercise any portion of the New Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99%
(or, upon election of the holder, 9.99%) of the number of shares of our Common Stock outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of the New Warrants. However, any holder may increase
or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.

In the event
of a Fundamental Transaction (as such term is defined in the New Warrant), then the successor entity will succeed to, and be substituted
for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the
New Warrants with the same effect as if such successor entity had been named in the warrant itself. If holders of Common Stock are given
a choice as to the securities, cash, or property to be received in a Fundamental Transaction, then the holder shall be given the same
choice as to the consideration it receives upon any exercise of the New Warrants following such Fundamental Transaction. In addition,
the successor entity, at the request of holders of New Warrants, will be obligated to purchase any unexercised portion of the New Warrants
in